Literature DB >> 22298989

Utility of IL-28B Polymorphisms in the Era of Direct-Acting Antiviral Therapy.

Stuart C Gordon1.   

Abstract

Entities:  

Year:  2011        PMID： 22298989      PMCID： PMC3264937     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

Authors:  Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Kazuaki Chayama; Yusuke Nakamura; Hiromitsu Kumada
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

2.  Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children.

Authors:  Angeles Ruiz-Extremera; José Antonio Muñoz-Gámez; María Angustias Salmerón-Ruiz; Paloma Muñoz de Rueda; Rosa Quiles-Pérez; Ana Gila-Medina; Jorge Casado; Ana Belén Martín; Laura Sanjuan-Nuñez; Angel Carazo; Esther José Pavón; Esther Ocete-Hita; Josefa León; Javier Salmerón
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

3.  Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.

Authors:  Michael R Charlton; Alexander Thompson; Bart J Veldt; Kym Watt; Hans Tillmann; John J Poterucha; Julie K Heimbach; David Goldstein; John McHutchison
Journal:  Hepatology       Date:  2011-01       Impact factor: 17.425

Review 4.  Hepatitis C pharmacogenetics: state of the art in 2010.

Authors:  Nezam H Afdhal; John G McHutchison; Stefan Zeuzem; Alessandra Mangia; Jean-Michel Pawlotsky; Jeffrey S Murray; Kevin V Shianna; Yasuhito Tanaka; David L Thomas; David R Booth; David B Goldstein
Journal:  Hepatology       Date:  2011-01       Impact factor: 17.425

5.  Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.

Authors:  A J Muir; K-Q Hu; S C Gordon; K Koury; N Boparai; S Noviello; J K Albrecht; M S Sulkowski; J McCone
Journal:  J Viral Hepat       Date:  2010-11-25       Impact factor: 3.728
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.